Needham & Company reiterated a "buy" rating for CONMED stock, according a Street Insider report.
Here are three notes:
1. Needham & Company also raised CONMED's price target to $52.
2. Needham & Company analyst Mike Matson noted that the company's new management, sales incentive changes, sales force hires and new products will help "drive revenue growth into the mid-single digits or better over the next two years" and he expects this to "drive EBITDA and multiple expansion."
3. CONMED shares closed at $46.06 on May 1.